STAAR Surgical to Report First Quarter Results on May 3, 2023

Rhea-AI Summary

STAAR Surgical Company (NASDAQ: STAA) will release its financial results for Q1 2023 on May 3, 2023, after market close. The company is known for developing implantable lenses to enhance vision and has sold over 2 million ICLs in over 75 countries. A conference call will follow at 4:30 PM Eastern to discuss operational progress and financial outcomes. Interested parties can access the call via phone or the live webcast from STAAR's investor relations website. A replay of the call will be available for a week afterward. With a commitment to ophthalmic surgery for over 40 years, STAAR continues to innovate and expand its reach in the vision correction market.

Positive

• Over 2 million ICLs sold to date.
• Products marketed in over 75 countries.
• Strong commitment to innovation in ophthalmic surgery.

Negative

• None.

LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that it will release financial results for the first quarter ended March 31, 2023 on Wednesday, May 3, 2023 after the market close.

STAAR will host a conference call and webcast on Wednesday, May 3 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference call (Access Code 835957), please dial 833-470-1428 for domestic participants and 404-975-4839 for international participants. The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com.

A taped replay of the conference call (Replay Code 208036) will be available beginning approximately one hour after the call’s conclusion for seven days. This replay can be accessed by dialing 866-813-9403 for domestic callers and 929-458-6194 for international callers. An archived webcast will also be available at www.staar.com.

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL”, which includes the EVO ICL™ product line. More than 2,000,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: EVOICL.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company’s website at www.staar.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20230419005424/en/

Investors & Media

Brian Moore

Vice President, Investor, Media Relations and Corporate Development

(626) 303-7902, Ext. 3023

bmoore@staar.com

Source: STAAR Surgical Company

FAQ

When will STAAR Surgical release its Q1 2023 financial results?

STAAR Surgical will release its Q1 2023 financial results on May 3, 2023, after the market close.

What time is the STAAR Surgical conference call on May 3, 2023?

The conference call will be held at 4:30 PM Eastern / 1:30 PM Pacific on May 3, 2023.

How can I access the STAAR Surgical conference call?

You can access the conference call by dialing 833-470-1428 for domestic participants or 404-975-4839 for international participants.

What is the significance of STAAR's ICL product line?

STAAR's ICL product line offers patients visual freedom and reduces reliance on glasses or contact lenses.